All In Biotech

Drug Trial Radar · NCT07750574

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

A Randomized, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral Flonoltinib Maleate in Patients With JAK Inhibitor Treatment-Naïve or Resistant Myelofibrosis

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Sponsor type
Industry
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn which of three different doses of Flonoltinib Maleate taken by mouth daily works best to treat adult patients with myelofibrosis in whom the most common approved therapy has failed to adequately control the disease. It will also learn about the safety of the three different daily doses of Flonoltinib Maleate. The main questions it aims to answer are: Which dose is the best at controlling the symptoms and signs of organ damage caused by myelofibrosis? What medical problems do participants have when taking the three different doses of Flonoltinib Maleate? Researchers will compare the three different doses of Flonoltinib Maleate to see which dose is best to treat patients with myelofibrosis. Participants will: Take Flonoltinib Maleate every day for as long as it seems to be of benefit to them in terms of controlling myelofibrosis. Visit the clinic for checkups and tests after giving fully informed written consent confirming that they would like to consider entering the study. Visit the clinic for checkups and tests when on the study once every 2 weeks for the first 2 months, every 4 weeks after that, and when coming off study therapy. Keep a diary of their symptoms.

Conditions

  • Myelofibrosis
  • Myelofibrosis Due to and Following Polycythemia Vera
  • Myelofibrosis Transformation in Essential Thrombocythemia
  • Myelofibrosis With High Molecular Risk Mutations
  • Myelofibrosis With Myeloid Metaplasia
  • Myelofibrosis, Post ET
  • Myelofibrosis, Post PV
  • Myelofibrosis, Primary
  • Myelofibrosis; Anemia
  • Myelofibrosis,MF
  • Myelofibrosis (PMF)
  • Myeloid Metaplasia

Interventions

  • Flonoltinib Maleate orallyDrug

    Dose of Flonoltinib Maleate will be 50mg daily

  • Flonoltinib Maleate orallyDrug

    Dose of Flonoltinib Maleate will be 75mg daily

  • Flonoltinib Maleate orallyDrug

    Dose of Flonoltinib Maleate will be 100mg daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with ≥35% reduction in spleen volume as assessed by imaging from baseline to week 24Time frame: Baseline and at 24 weeks on study

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.